Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses

Vaccine

Volumn 34, Issue 51, 2016, Pages 6464-6471

  Zheng, Dan ^a   Chen, Shaoheng ^a   Qu, Di ^b   Chen, Jianjun ^c   Wang, Fuyan ^d   Zhang, Ran ^e   Chen, Ze ^a,e  

^a Shanghai Institute of Biological Products   (China)

^b FUDAN UNIVERSITY   (China)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

^d Central South University   (China)

^e HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Adjuvant; H7N9; Influenza; LAH HBc VLP

Indexed keywords

CHITOSAN; CORE PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; VIRUS LIKE PARTICLE VACCINE; DRUG CARRIER; EPITOPE; HEPATITIS B CORE ANTIGEN; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HEPATITIS B VIRUS; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H7N9); MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CROSS PROTECTION; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INTRANASAL DRUG ADMINISTRATION; METABOLISM; MONONUCLEAR CELL; ORTHOMYXOVIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHITOSAN; CROSS PROTECTION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EPITOPES; ESCHERICHIA COLI; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEPATITIS B CORE ANTIGENS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; LEUKOCYTES, MONONUCLEAR; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85001022561     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.026     Document Type: Article

References (37)

1. [1] WHO: H7N9 virus “one of the most lethal so far”. CNN. Available at: http://edition.cnn.com/2013/04/24/world/asia/china-birdflu/index.html [accessed 25 April 2013].
2. [2] Li, Q., Zhou, L., Zhou, M., Chen, Z., Li, F., Wu, H., et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 370 (2014), 520–532.
3. [3] Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368 (2013), 1888–1897.
4. [4] Lai, K.Y., Ng, G.W.Y., Wong, K.F., Hung, I.F.N., Hong, J.K.F., Cheng, F.F., et al. Human H7N9 avian influenza virus infection: a review and pandemic risk assessment. Emerg Microbes Infect, 2, 2013, e48.
5. [5] Gao, Y., Zhang, Y., Shinya, K., Deng, G., Jiang, Y., Li, Z., et al. Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog, 5, 2009, e1000709.
6. [6] Cox, R.J., Madhun, A.S., Hauge, S., Sjursen, H., Major, D., Kuhne, M., et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27 (2009), 1889–1897.
7. [7] Couch, R.B., Patel, S.M., Wade-Bowers, C.L., Niño, D., A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS ONE, 7, 2012, e49704.
8. [8] Chen, J.R., Yu, Y.H., Tseng, Y.C., Chiang, W.L., Chiang, M.F., Ko, Y.A., et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A 111 (2014), 2467–2481.
9. [9] Wang, T.T., Tan, G.S., Hai, R., Pica, N., Petersen, E., Moran, T.M., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog, 6, 2010, e1000796.
10. [10] Zhang, H., Xu, B., Chen, Q., Chen, J., Chen, Z., Characterization of an H10N8 influenza virus isolated from Dongting lake wetland. Virol J, 8, 2011, 42.
11. [11] Luo, J., Zheng, D., Zhang, W., Fang, F., Wang, H., Sun, Y., et al. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol J, 9, 2012, 286.
12. [12] Chen, S., Zheng, D., Li, C., Zhang, W., Xu, W., Liu, X., et al. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope. BioMed Res Int, 2015 Article ID 901817.
13. [13] Lin, J., Zhang, J., Dong, X., Fang, H., Chen, J., Su, N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006), 991–997.
14. [14] Ann, H.R., Thomas, G.F., Johan, V.H., Jeffery, K.T., Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 96 (1999), 1651–1656.
15. [15] Hashem, A.M., Prospects of HA-based universal influenza vaccine. Biomed Res Int, 2015, 2015, 414637.
16. [16] Ellebedy, A.H., Krammer, F., Li, G.M., Miller, M.S., Chiu, C., Wrammert, J., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111 (2014), 13133–13138.
17. [17] Bommakanti, G., Citron, M.P., Hepler, R.W., Callahan, C., Heidecker, G.J., Najar, T.A., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 107 (2010), 13701–13706.
18. [18] Wang, T.T., Tan, G.S., Hai, R., Pica, N., Ngai, L., Ekiert, D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 107 (2010), 18979–18984.
19. [19] Sominskaya, I., Skrastina, D., Dislers, A., Vasiljev, D., Mihailova, M., Ose, V., et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol 17 (2010), 1027–1033.
20. [20] Pumpens, P., Razanskas, R., Pushko, P., Renhof, R., Gusars, I., Skrastina, D., et al. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology 45 (2002), 24–32.
21. [21] Filette, M.D., Jou, W.M., Birkett, A., Lyons, K., Schultz, B., Tonkyro, A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 (2005), 149–161.
22. [22] Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 (1999), 1157–1163.
23. [23] Filette, M.D., Ramne, A., Birkett, A., Lycke, N., Löwenadler, B., Jou, W.M., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24 (2006), 544–551.
24. [24] Hopkins, S., Kraehenbuhl, J.P., Schödel, F., Potts, A., Peterson, D., de Grandi, P., et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 63 (1995), 3279–3286.
25. [25] Wu, H.Y., Nguyen, H.H., Russell, M.W., Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol 46 (1997), 506–513.
26. [26] Tamura, S., Ito, Y., Asanuma, H., Hirabayashi, Y., Suzuki, Y., Nagamine, T., et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 149 (1992), 981–988.
27. [27] Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., Tamura, S., et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8 (1990), 243–248.
28. [28] Mazanec, M.B., Kaetzel, C.S., Lamm, M.E., Fletcher, D., Nedrud, J.G., Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A 89 (1992), 6901–6905.
29. [29] Mazanec, M.B., Coudret, C.L., Fletcher, D.R., Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 69 (1995), 1339–1343.
30. [30] Yan, H., Lamm, M.E., Björling, E., Huang, Y.T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. J Virol 76 (2002), 10972–10979.
31. [31] Coffman, R.L., Lebman, D.A., Rothman, P., Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54 (1993), 229–270.
32. [32] Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3 (2013), 521–530.
33. [33] Houser, K., Subbarao, K., Influenza vaccines: challenges and solutions. Cell Host Microbe 17 (2015), 295–300.
34. [34] Ekiert, D.C., Bhabha, G., Elsliger, M.A., Friesen, R.H.E., Jongeneelen, M., Throsby, M., et al. Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy. Science 324 (2009), 246–251.
35. [35] Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 1, 2010 e00018-10.
36. [36] Krammer, F., Margine, I., Hai, R., Flood, A., Hirsh, A., Tsvetnitsky, V., et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88 (2014), 2340–2343.
37. [37] Nabel, G.J., Fauci, A.S., Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 16 (2010), 1389–1391.